Potential Role of Growth Hormone in Impairment of Insulin Signaling in Skeletal Muscle, Adipose Tissue, and Liver of Rats Chronically Treated with Arginine


Autoria(s): BARBOSA, Thais de Castro; CARVALHO, Jose Edgar Nicoletti de; POYARES, Leonice Lourenco; BORDIN, Silvana; MACHADO, Ubiratan Fabres; NUNES, Maria Tereza
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2009

Resumo

We have shown that rats chronically treated with Arginine (Arg), although normoglycemic, exhibit hyperinsulinemia and decreased blood glucose disappearance rate after an insulin challenge. Attempting to investigate the processes underlying these alterations, male Wistar rats were treated with Arg (35 mg/d), in drinking water, for 4 wk. Rats were then acutely stimulated with insulin, and the soleus and extensorum digitalis longus muscles, white adipose tissue (WAT), and liver were excised for total and/or phosphorylated insulin receptor (IR), IR substrate 1/2, Akt, Janus kinase 2, signal transducer and activator of transcription (STAT) 1/3/5, and p85 alpha/55 alpha determination. Muscles and WAT were also used for plasma membrane (PM) and microsome evaluation of glucose transporter (GLUT) 4 content. Pituitary GH mRNA, GH, and liver IGF-I mRNA expression were estimated. It was shown that Arg treatment: 1) did not affect phosphotyrosine-IR, whereas it decreased phosphotyrosine-IR substrate 1/2 and phosphoserine-Akt content in all tissues studied, indicating that insulin signaling is impaired at post-receptor level; 2) decreased PM GLUT4 content in both muscles and WAT; 3) increased the pituitary GH mRNA, GH, and liver IGF-I mRNA expression, the levels of phosphotyrosine-STAT5 in both muscles, phosphotyrosine-Janus kinase 2 in extensorum digitalis longus, phosphotyrosine-STAT3 in liver, and WAT as well as total p85 alpha in soleus, indicating that GH signaling is enhanced in these tissues; and 4) increased p55 alpha total content in muscles, WAT, and liver. The present findings provide the molecular mechanisms by which insulin resistance and, by extension, reduced GLUT4 content in PM of muscles and WAT take place after chronic administration of Arg, and further suggest a putative role for GH in its genesis, considering its diabetogenic effect. (Endocrinology 150: 2080-2086, 2009)

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo[02/07384-4]

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

CNPq Conselho Nacional de Pesquisa e Desenvolvimento

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Identificador

ENDOCRINOLOGY, v.150, n.5, p.2080-2086, 2009

0013-7227

http://producao.usp.br/handle/BDPI/27906

10.1210/en.2008-1487

http://dx.doi.org/10.1210/en.2008-1487

Idioma(s)

eng

Publicador

ENDOCRINE SOC

Relação

Endocrinology

Direitos

restrictedAccess

Copyright ENDOCRINE SOC

Palavras-Chave #ORAL L-ARGININE #RECEPTOR SUBSTRATE-1 #IN-VIVO #PHOSPHOINOSITIDE 3-KINASE #ANTERIOR-PITUITARY #AMINO-ACIDS #RESISTANCE #METABOLISM #EXPRESSION #MECHANISM #Endocrinology & Metabolism
Tipo

article

original article

publishedVersion